Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

Item

http://www.wikidata.org/entity/Q37858327

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 March 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

@en

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

@nl

type

Item

label

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

@en

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

@nl

prefLabel

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

@en

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

@nl

P1476

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective

@en

P2093

Fernando Leal da Costa

http://www.w3.org/2001/XMLSchema#string

Hila Magen-Nativ

http://www.w3.org/2001/XMLSchema#string

Jamie Cavenagh

http://www.w3.org/2001/XMLSchema#string

Jean-Luc Harousseau

http://www.w3.org/2001/XMLSchema#string

Jesús San-Miguel

http://www.w3.org/2001/XMLSchema#string

Joan Bladé

http://www.w3.org/2001/XMLSchema#string

Johannes Drach

http://www.w3.org/2001/XMLSchema#string

Martin Kropff

http://www.w3.org/2001/XMLSchema#string

Meral Beksac

http://www.w3.org/2001/XMLSchema#string

Michel Delforge

http://www.w3.org/2001/XMLSchema#string

P2860

Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.

The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function.

Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.

Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciences

Homozygous deletion mapping in myeloma samples identifies genes and an expression signature relevant to pathogenesis and outcome

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance.

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.

Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy

P304

388-403

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2010-0386

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

Hartmut Goldschmidt

Meletios A. Dimopoulos

P577

2011-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

50868023

http://www.w3.org/2001/XMLSchema#string

P698

21441574

http://www.w3.org/2001/XMLSchema#string

P932

3228121

http://www.w3.org/2001/XMLSchema#string